Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases

The soluble urokinase plasminogen activator receptor (suPAR) is the bioactive form of uPAR, a membrane-bound glycoprotein, and it is primarily expressed on the surface of immunologically active cells. Mirroring local inflammation and immune activation, suPAR has gained interest as a potential prognostic biomarker in several inflammatory diseases. Indeed, in many diseases, including cancer, diabetes, cardiovascular diseases, kidney diseases, and inflammatory disorders, higher suPAR concentrations have been associated with disease severity, disease relapse, and mortality. Our review describes and discusses the supporting literature concerning the promising role of suPAR as a biomarker in different autoimmune rheumatic and non-rheumatic diseases.

[1]  L. Rasmussen,et al.  Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation , 2021, Frontiers in Immunology.

[2]  M. Krajewska,et al.  Immune Cells Profiling in ANCA-Associated Vasculitis Patients—Relation to Disease Activity , 2021, Cells.

[3]  B. Vásárhelyi,et al.  Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity , 2021, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[4]  J. Jeppesen,et al.  Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis , 2021, PloS one.

[5]  H. Enocsson,et al.  Serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlates with disease activity in early rheumatoid arthritis and reflects joint damage over time. , 2021, Translational research : the journal of laboratory and clinical medicine.

[6]  A. Uzawa,et al.  Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study , 2020, Clinical and experimental immunology.

[7]  E. Kontopantelis,et al.  National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study , 2020, BMJ.

[8]  A. Eid,et al.  SuPAR, a potential inflammatory mediator in psoriasis pathogenesis , 2020, Clinical and experimental pharmacology & physiology.

[9]  O. Karadag,et al.  Management of Behcet's syndrome. , 2020, Rheumatology.

[10]  Yongman Lv,et al.  The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis , 2020, Mediators of inflammation.

[11]  I. Bruce,et al.  Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. , 2020, Journal of autoimmunity.

[12]  G. Alarcón,et al.  Lupus: the new epidemic , 2019, Lupus.

[13]  M. Nowicki,et al.  Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis. , 2018, Minerva pediatrica.

[14]  K. Mitsuyama,et al.  Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization , 2017, International journal of molecular medicine.

[15]  M. Speeckaert,et al.  The intriguing role of soluble urokinase receptor in inflammatory diseases , 2017, Critical reviews in clinical laboratory sciences.

[16]  M. Manetti.  Emerging biomarkers in systemic sclerosis , 2016, Current opinion in rheumatology.

[17]  A. Chawla,et al.  Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? , 2016, Indian journal of endocrinology and metabolism.

[18]  R. Mangues,et al.  uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy , 2016, Oncotarget.

[19]  J. Jensen,et al.  suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. , 2016, European journal of endocrinology.

[20]  R. Kesli,et al.  Plasma‐soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity , 2016, International journal of rheumatic diseases.

[21]  T. Åkerstedt,et al.  Diurnal Variation of Circulating Interleukin-6 in Humans: A Meta-Analysis , 2016, bioRxiv.

[22]  B. Vásárhelyi,et al.  Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis , 2015, Clinical chemistry and laboratory medicine.

[23]  F. Yu,et al.  Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China , 2015, Lupus.

[24]  T. Hansen,et al.  Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes , 2015, Journal of internal medicine.

[25]  H. Ullum,et al.  Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants , 2014, PloS one.

[26]  L. Öhman,et al.  The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. , 2014, Journal of Crohn's & colitis.

[27]  G. Hatemi,et al.  Management of Behçet's syndrome , 2014, Current opinion in rheumatology.

[28]  J. Wetterö,et al.  Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. , 2013, Translational research : the journal of laboratory and clinical medicine.

[29]  B. Vásárhelyi,et al.  Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[30]  Yeon-Ah Lee,et al.  Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13 , 2012, Rheumatology International.

[31]  M. Baron,et al.  Association of C‐reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group , 2012, Arthritis care & research.

[32]  E. Savilahti,et al.  Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease , 2012, Scandinavian journal of gastroenterology.

[33]  B. Vásárhelyi,et al.  Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission , 2012, Clinical chemistry and laboratory medicine.

[34]  J. Vincent,et al.  suPAR as a prognostic biomarker in sepsis , 2012, BMC Medicine.

[35]  Anastasia Antonopoulou,et al.  Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. , 2011, The Journal of infection.

[36]  M. Silverberg,et al.  C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. , 2011, Journal of Crohn's & colitis.

[37]  Yeon-Ah Lee,et al.  Increased levels of thymosin β4 in synovial fluid of patients with rheumatoid arthritis: association of thymosin β4 with other factors that are involved in inflammation and bone erosion in joints , 2011, International journal of rheumatic diseases.

[38]  A. Laurenzana,et al.  The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation. , 2011, Current pharmaceutical design.

[39]  T. Hansen,et al.  Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population , 2010, Journal of internal medicine.

[40]  M. Menshikov,et al.  Release of the Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) by Activated Neutrophils in Rheumatoid Arthritis , 2010, Inflammation.

[41]  Jesper Eugen-Olsen,et al.  suPAR: The Molecular Crystal Ball , 2009, Disease markers.

[42]  D. Sanders,et al.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity , 2009, The Lancet Neurology.

[43]  A. Staiano,et al.  Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[44]  J. Braun,et al.  Ankylosing spondylitis , 2007, The Lancet.

[45]  N. Brünner,et al.  Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling , 2001, The International journal of biological markers.

[46]  B. Binder,et al.  Mechanisms of Signaling through Urokinase Receptor and the Cellular Response , 1999, Thrombosis and Haemostasis.

[47]  N. Brünner,et al.  Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis , 1999, Annals of the rheumatic diseases.

[48]  M. Cerinic,et al.  Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface. , 1998, Life sciences.

[49]  R. Stephens,et al.  The urokinase receptor , 1998 .

[50]  T. Plesner,et al.  Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPAR , 1997, Stem cells.

[51]  H. Nielsen,et al.  ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. , 1997, Clinical chemistry.

[52]  S. Edwards,et al.  Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. , 1997, Immunology today.

[53]  S. Abramson,et al.  The neutrophil in rheumatoid arthritis. , 1995, Rheumatic diseases clinics of North America.

[54]  N. Brünner,et al.  The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion , 1995 .

[55]  N. E. Hansen,et al.  The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria , 1995, British journal of haematology.

[56]  H. Johnsen,et al.  Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. , 1994, American journal of clinical pathology.

[57]  Julie Wendt,et al.  Immune , 2021, Integrative Geriatric Nutrition.

[58]  R. Kesli,et al.  Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity. , 2015, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

[59]  J. Eugen-Olsen,et al.  The molecular crystal ball , 2014 .

[60]  B. Vásárhelyi,et al.  Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis. , 2013, Joint, bone, spine : revue du rhumatisme.

[61]  C. Marshall,et al.  Regulation of cell signalling by uPAR , 2010, Nature Reviews Molecular Cell Biology.